Day C A, White B, Thein H H, Doab A, Dore G J, Bates A, Holden J, Maher L
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia.
AIDS Care. 2008 Jan;20(1):116-23. doi: 10.1080/09540120701426524.
Testing injecting drug users (IDUs) for HIV and hepatitis C virus (HCV) provides a useful opportunity for health promotion, risk-reduction assessment and counselling, and increases opportunities for treatment assessment, yet little is known about IDUs' experience of testing. This study aimed to examine the experiences of testing among IDUs recruited through primary healthcare and drug treatment services. Almost all the 229 participants recruited had been previously tested for HIV (96%) and HCV (97%), a median of five and four times respectively. Reasons for seeking testing were similar for both HIV and HCV, the most common being to protect others (72 and 74%, respectively), blood/needle exposure (66 and 70%, respectively) and to receive early treatment (66%, both). The most common locations for testing were general medical practices (GPs) (53%), specialised clinics (45%) and methadone clinics (43%). Preferred locations were similar for HIV and HCV testing: methadone clinics (47 and 48%, respectively), GPs (42%, both), specialised clinics (32%, both). The most common reasons for delaying testing were being anxious about waiting for results (66%), scared or afraid of finding out results (65%) and having trouble keeping appointments (64%). The majority of participants (HIV 62%; HCV 59%) reported that they would prefer pre-test counselling to be delivered in person rather than receiving written information and would prefer test results to be delivered face-to-face (HIV 83%; HCV 80%). High prevalence of testing suggests good uptake and high acceptability among this population in Australia. Specialised services for drug users such as methadone clinics and primary healthcare are suitable locations to provide access to testing.
对注射吸毒者进行艾滋病毒和丙型肝炎病毒检测，为健康促进、风险降低评估及咨询提供了有益契机，还增加了治疗评估机会，但对于注射吸毒者的检测体验却知之甚少。本研究旨在调查通过初级医疗保健和药物治疗服务招募的注射吸毒者的检测体验。招募的229名参与者几乎都曾接受过艾滋病毒检测（96%）和丙型肝炎病毒检测（97%），检测次数中位数分别为5次和4次。艾滋病毒和丙型肝炎病毒检测的寻求检测原因相似，最常见的是保护他人（分别为72%和74%）、血液/针头暴露（分别为66%和70%）以及接受早期治疗（均为66%）。最常见的检测地点是普通医疗诊所（53%）、专科诊所（45%）和美沙酮诊所（43%）。艾滋病毒和丙型肝炎病毒检测的首选地点相似：美沙酮诊所（分别为47%和48%）、普通医疗诊所（均为42%）、专科诊所（均为32%）。推迟检测的最常见原因是担心等待结果（66%）、害怕得知结果（65%）以及难以遵守预约（64%）。大多数参与者（艾滋病毒检测为62%；丙型肝炎病毒检测为59%）报告称，他们更希望面对面进行检测前咨询，而非接收书面信息，并且更希望面对面告知检测结果（艾滋病毒检测为83%；丙型肝炎病毒检测为80%）。高检测率表明在澳大利亚的这一人群中检测接受度良好且接受程度高。为吸毒者提供的专业服务，如美沙酮诊所和初级医疗保健，是提供检测服务的合适场所。
